SG Americas Securities LLC Reduces Holdings in The Cooper Companies, Inc. (NASDAQ:COO)

SG Americas Securities LLC reduced its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 96.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,246 shares of the medical device company’s stock after selling 91,090 shares during the period. SG Americas Securities LLC’s holdings in Cooper Companies were worth $358,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in COO. Benjamin F. Edwards & Company Inc. increased its holdings in Cooper Companies by 248.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock worth $25,000 after purchasing an additional 174 shares during the last quarter. Innealta Capital LLC bought a new stake in shares of Cooper Companies in the second quarter worth $25,000. Covestor Ltd raised its holdings in Cooper Companies by 305.9% in the first quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock valued at $28,000 after acquiring an additional 208 shares in the last quarter. Crewe Advisors LLC boosted its stake in Cooper Companies by 286.4% during the 2nd quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 252 shares during the last quarter. Finally, Tortoise Investment Management LLC grew its holdings in Cooper Companies by 75.4% during the 2nd quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company’s stock worth $34,000 after acquiring an additional 169 shares in the last quarter. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, COO Daniel G. Mcbride sold 114,992 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the transaction, the chief operating officer now directly owns 44,696 shares of the company’s stock, valued at approximately $4,714,534.08. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, COO Daniel G. Mcbride sold 114,992 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total value of $12,129,356.16. Following the completion of the transaction, the chief operating officer now directly owns 44,696 shares in the company, valued at $4,714,534.08. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Agostino Ricupati sold 1,601 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total value of $172,956.03. Following the sale, the chief accounting officer now directly owns 4,818 shares in the company, valued at approximately $520,488.54. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 256,373 shares of company stock worth $27,637,427. 2.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on COO shares. Piper Sandler increased their price target on shares of Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, August 29th. Morgan Stanley increased their target price on Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a report on Tuesday, September 10th. Robert W. Baird boosted their price target on Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday, August 29th. Stifel Nicolaus restated a “buy” rating and set a $115.00 price objective (up from $110.00) on shares of Cooper Companies in a research note on Thursday, August 29th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a report on Thursday, August 29th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $115.00.

Cooper Companies Stock Up 1.4 %

COO stock opened at $108.26 on Friday. The stock has a market cap of $21.56 billion, a PE ratio of 63.68, a price-to-earnings-growth ratio of 2.56 and a beta of 0.98. The firm’s 50-day simple moving average is $104.28 and its 200 day simple moving average is $96.45. The Cooper Companies, Inc. has a fifty-two week low of $75.93 and a fifty-two week high of $112.38. The company has a quick ratio of 1.18, a current ratio of 1.99 and a debt-to-equity ratio of 0.33.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.91 by $0.05. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $997.30 million. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. Cooper Companies’s revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.84 earnings per share. As a group, sell-side analysts predict that The Cooper Companies, Inc. will post 3.65 EPS for the current year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.